TY - JOUR
T1 - Comparison of human selenoprotein P determinants in serum between our original methods and commercially available kits
AU - Saito, Yoshiro
AU - Misu, Hirofumi
AU - Takayama, Hiroaki
AU - Takashima, Shin Ichiro
AU - Usui, Soichiro
AU - Takamura, Masayuki
AU - Kaneko, Shuichi
AU - Takamura, Toshinari
AU - Noguchi, Noriko
N1 - Funding Information:
This work was supported in part by KAKENHI Grant Number 25292078 and 17H03821 from the Japan Society for the Promotion of Science (JSPS) and Ministry of Education, Culture, Sports, Science and Technology (MEXT)-Supported Program for the Strategic Research Foundation at Private Universities.
Funding Information:
Acknowledgments This work was supported in part by KAKENHI Grant Number 25292078 and 17H03821 from the Japan Society for the Promotion of Science (JSPS) and Ministry of Education, Culture, Sports, Science and Technology (MEXT)-Supported Program for the Strategic Research Foundation at Private Universities.
Publisher Copyright:
© 2018 The Pharmaceutical Society of Japan.
PY - 2018
Y1 - 2018
N2 - Selenoprotein P (SeP) is a selenium (Se)-rich extracellular protein. SeP is identified as a hepatokine, causing insulin resistance in type 2 diabetes. Thus, the measurement of SeP in serum has received much attention, and several enzyme-linked immunosorbent assay (ELISA) kits for SeP determination are now commercially available. In the present study, we determined the serum SeP levels by our original ELISA and sol particle homogeneous immunoassay (SPIA) methods and also by commercially available kits, and these determinants were compared. We found a kit-dependent correlation of the determinants with our methods. These results suggest that the selection of kit is critical for comparison with our previous reports and for discussing the relationship between the serum SeP levels and disease condition.
AB - Selenoprotein P (SeP) is a selenium (Se)-rich extracellular protein. SeP is identified as a hepatokine, causing insulin resistance in type 2 diabetes. Thus, the measurement of SeP in serum has received much attention, and several enzyme-linked immunosorbent assay (ELISA) kits for SeP determination are now commercially available. In the present study, we determined the serum SeP levels by our original ELISA and sol particle homogeneous immunoassay (SPIA) methods and also by commercially available kits, and these determinants were compared. We found a kit-dependent correlation of the determinants with our methods. These results suggest that the selection of kit is critical for comparison with our previous reports and for discussing the relationship between the serum SeP levels and disease condition.
KW - Commercially available kit
KW - Enzyme-linked immunosorbent assay (ELISA)
KW - Monoclonal antibody
KW - Selenoprotein P
KW - Sol particle homogeneous immunoassay (SPIA)
UR - http://www.scopus.com/inward/record.url?scp=85046673823&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85046673823&partnerID=8YFLogxK
U2 - 10.1248/bpb.b18-00046
DO - 10.1248/bpb.b18-00046
M3 - Article
C2 - 29709922
AN - SCOPUS:85046673823
VL - 41
SP - 828
EP - 832
JO - Biological and Pharmaceutical Bulletin
JF - Biological and Pharmaceutical Bulletin
SN - 0918-6158
IS - 5
ER -
